(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 35.33% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.11%.
Eton Pharmaceuticals's revenue in 2026 is $80,775,000.On average, 5 Wall Street analysts forecast ETON's revenue for 2026 to be $2,929,535,799, with the lowest ETON revenue forecast at $2,715,679,958, and the highest ETON revenue forecast at $3,097,062,573. On average, 5 Wall Street analysts forecast ETON's revenue for 2027 to be $3,996,905,087, with the lowest ETON revenue forecast at $3,660,760,157, and the highest ETON revenue forecast at $4,418,996,162.
In 2028, ETON is forecast to generate $5,461,809,408 in revenue, with the lowest revenue forecast at $4,252,015,077 and the highest revenue forecast at $6,688,792,969.